Elidah, a healthcare technology company known for developing FDA-cleared non-invasive, wearable treatments for urinary incontinence in women, has recently announced the completion of its Series A funding round. The company has successfully secured an undisclosed amount of investment, led by Blu Venture Investors and supported by contributions from Right Side Capital and Integral Private Wealth Advisors. This financial milestone is set to support Elidah’s mission to expand its outreach and improve the distribution of its innovative products, Elitone and Elitone URGE, which aim to address the widespread issue of urinary incontinence affecting one in three women globally.
Gloria Kolb, CEO and co-founder of Elidah comments: “Securing funding is so hard, so we are very fortunate and thankful. However, we are very aware that every dollar in Femtech has to stretch and go further than in other industries. The burden is now on us to make sure that we are successful not only for our customers, but so that other investors see Femtechs as profitable investments.”
Elidah’s recent achievements include receiving the Innovation Award at CES 2024 in the Accessibility and Aging Tech category for its product Elitone URGE. This award emphasizes the company’s ability to innovate and lead in the healthcare technology sector, especially in areas that enhance the quality of life for women.
With over 15,000 women already treated according to the company, Elidah plans to use the new funding to expand its reach, streamline insurance processes, and explore new markets. The company’s efforts are aimed at making its treatments more accessible and effective for women worldwide, further emphasizing the importance of non-invasive healthcare solutions in improving the quality of life and economic participation of women globally.
